Hydromer, Inc. (HYDI) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HYDI steht fuer Hydromer, Inc., ein Basic Materials-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Bewertet mit 48/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 15. März 2026Hydromer, Inc. (HYDI) Werkstoff- & Rohstoffexposure
Hydromer, Inc., founded in 1980, develops and sells hydrophilic polymer-based products and services across medical, cosmetic, and industrial sectors. Operating through Polymer Research and Medical Products segments, the company offers specialized coatings, hydrogels, and contract services, distinguishing itself through patented technologies and diverse applications.
Investmentthese
Hydromer, Inc. presents a focused investment opportunity within the specialty chemicals sector, driven by its patented hydrophilic polymer technology. The company's diverse applications across medical, cosmetic, and industrial fields provide revenue streams. A key value driver is the expansion of its medical coatings and services segment, targeting a growing market for biocompatible materials. The company's current negative P/E ratio of -0.59 and a negative profit margin of -42.8% indicate potential for turnaround through strategic partnerships and cost optimization. Growth catalysts include increased licensing agreements and expansion of contract coating services. Investors should monitor gross margin improvements from its current 48.9% and beta of -0.93.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Operates in two segments: Polymer Research and Medical Products, focusing on hydrophilic polymer technology.
- Offers a diverse range of products including medical coatings, cosmetic intermediaries, and anti-fog coatings.
- Serves multiple sectors including medical, cosmetics, animal health, and industrial.
- Gross margin of 48.9% indicates strong potential for profitability with optimized operations.
- Negative Beta of -0.93 suggests the stock price is less volatile than the market average.
Wettbewerber & Vergleichsunternehmen
Staerken
- Patented hydrophilic polymer technology
- Diverse applications across multiple industries
- Specialized expertise in coating applications
- Established relationships with key customers
Schwaechen
- Negative profit margin
- Limited financial resources
- Small employee base
- Dependence on key patents
Katalysatoren
- Ongoing: Expansion of medical coatings and services segment driven by increasing demand for biocompatible materials.
- Ongoing: Increased licensing agreements for patented hydrophilic polymer technology.
- Upcoming: Potential partnerships with larger companies in the medical and cosmetic sectors by Q4 2026.
- Ongoing: Growth in cosmetic intermediaries segment due to consumer demand for high-performance products.
- Ongoing: Expansion of contract coating services to new industries such as automotive and aerospace.
Risiken
- Potential: Competition from larger chemical companies with greater resources and market share.
- Ongoing: Dependence on key patents and the risk of patent infringement.
- Potential: Economic downturn affecting demand for specialty chemical products.
- Ongoing: Limited financial resources and potential need for additional funding.
- Potential: Regulatory changes impacting the use of certain chemicals or coatings.
Wachstumschancen
- Expansion of Medical Coatings and Services: The market for medical coatings is growing due to increasing demand for biocompatible materials in medical devices. Hydromer can capitalize on this by expanding its range of medical coatings and services, targeting a market estimated at $15 billion by 2028. A focus on innovative coatings for implantable devices and drug delivery systems could drive significant revenue growth.
- Increased Licensing Agreements: Hydromer's patented hydrophilic polymer technology can be leveraged through licensing agreements with other companies in the medical, cosmetic, and industrial sectors. This provides a low-risk revenue stream and expands the reach of its technology. Securing 2-3 new licensing agreements annually could generate substantial royalty income.
- Growth in Cosmetic Intermediaries: The demand for specialized ingredients in the cosmetics industry is increasing, driven by consumer demand for high-performance products. Hydromer can expand its offerings of cosmetic intermediaries, targeting a market estimated at $40 billion by 2027. Developing new hydrogel-based ingredients for skincare and haircare products could drive significant growth.
- Expansion of Contract Coating Services: Hydromer can leverage its expertise in coating technology to offer contract coating services to companies in various industries. This provides a stable revenue stream and allows the company to utilize its manufacturing facilities efficiently. Targeting industries such as automotive, aerospace, and electronics could drive growth in this segment.
- Development of Anti-Fog/Anti-Frost Coatings: The market for anti-fog and anti-frost coatings is growing, driven by demand for improved visibility and safety in various applications. Hydromer can expand its offerings in this area, targeting industries such as automotive, aerospace, and consumer electronics. Developing new coatings with enhanced durability and performance could drive significant revenue growth.
Chancen
- Expansion into new markets and applications
- Increased licensing agreements
- Strategic partnerships with larger companies
- Growing demand for biocompatible materials
Risiken
- Competition from larger chemical companies
- Patent infringement
- Economic downturn
- Regulatory changes
Wettbewerbsvorteile
- Patented hydrophilic polymer technologies
- Specialized expertise in coating applications
- Long-standing relationships with customers in key industries
- Proprietary formulations and manufacturing processes
Ueber HYDI
Hydromer, Inc., established in 1980, is a technology-driven company focused on inventing, developing, patenting, licensing, manufacturing, and selling hydrophilic polymer-based products and services. The company operates through two primary segments: Polymer Research and Medical Products. Its offerings include medical coatings and services, medical hydrogels, cosmetic intermediaries, and anti-fog/anti-frost condensation control coating products. Hydromer also provides cosmetics and personal care products, along with watercraft hull coating products. Furthermore, Hydromer, Inc. offers engineering and contract coating services, catering to the medical, cosmetics, animal health, and industrial fields. Based in Branchburg, New Jersey, Hydromer serves both domestic and international markets, leveraging its proprietary technologies to deliver specialized solutions. The company's evolution has been marked by a consistent focus on innovation and application of hydrophilic polymers across diverse industries, positioning it as a key player in specialty chemical solutions.
Was das Unternehmen tut
- Invents and develops hydrophilic polymer-based products.
- Patents and licenses its proprietary technologies.
- Manufactures and sells medical coatings and services.
- Offers medical hydrogels for various applications.
- Provides cosmetic intermediaries for personal care products.
- Supplies anti-fog and anti-frost condensation control coatings.
- Offers engineering and contract coating services.
Geschaeftsmodell
- Develops and patents hydrophilic polymer technologies.
- Manufactures and sells specialized coatings and hydrogels.
- Licenses its technologies to other companies.
- Provides contract coating services to various industries.
Branchenkontext
Hydromer, Inc. operates within the specialty chemicals industry, which is characterized by innovation and customized solutions. The market is driven by demand for high-performance materials in sectors like healthcare, cosmetics, and industrial coatings. Key trends include a focus on biocompatibility, sustainability, and advanced material science. Hydromer competes with companies like CBNT, GBGD, GPHBF, INTK, and MGIDF, which offer similar specialty chemical products and services. The industry is experiencing growth in demand for specialized coatings and hydrogels, creating opportunities for companies with patented technologies and strong customer relationships.
Wichtige Kunden
- Medical device manufacturers
- Cosmetic and personal care product companies
- Industrial companies requiring specialized coatings
- Animal health product manufacturers
Finanzdaten
Chart & Info
Hydromer, Inc. (HYDI) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer HYDI verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer HYDI.
Kursziele
Wall-Street-Kurszielanalyse fuer HYDI.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von HYDI auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Michael Torti
CEO
Michael Torti serves as the CEO of Hydromer, Inc., overseeing the company's strategic direction and operations. His background includes extensive experience in the specialty chemicals industry, with a focus on polymer technology and coating applications. Torti has held various leadership positions in research and development, manufacturing, and sales, bringing a comprehensive understanding of the business. He is responsible for managing the company's 34 employees and driving innovation in hydrophilic polymer technology.
Erfolgsbilanz: Under Michael Torti's leadership, Hydromer, Inc. has focused on expanding its patented technology portfolio and strengthening relationships with key customers. He has overseen the development of new coating applications and the expansion of contract coating services. A key achievement has been the securing of new licensing agreements and the diversification of the company's product offerings. He has also focused on cost optimization and improving operational efficiency.
HYDI OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Hydromer, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with higher risk profiles due to factors such as financial distress, limited operating history, or regulatory issues. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Higher price volatility
- Potential for fraud or manipulation
- Lack of regulatory oversight
- Verify the company's financial statements and disclosures.
- Assess the company's business model and competitive position.
- Evaluate the management team and their track record.
- Research the company's legal and regulatory history.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any SEC filings or regulatory actions.
- Patented technology and intellectual property
- Established relationships with customers in key industries
- Experienced management team
- Positive customer reviews and testimonials
- Long operating history since 1980
HYDI Basic Materials Aktien-FAQ
What are the key factors to evaluate for HYDI?
Hydromer, Inc. (HYDI) currently holds an AI score of 48/100, indicating low score. Key strength: Patented hydrophilic polymer technology. Primary risk to monitor: Potential: Competition from larger chemical companies with greater resources and market share.. This is not financial advice.
How frequently does HYDI data refresh on this page?
HYDI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HYDI's recent stock price performance?
Recent price movement in Hydromer, Inc. (HYDI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Patented hydrophilic polymer technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HYDI overvalued or undervalued right now?
Determining whether Hydromer, Inc. (HYDI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HYDI?
Before investing in Hydromer, Inc. (HYDI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding HYDI to a portfolio?
Potential reasons to consider Hydromer, Inc. (HYDI) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Patented hydrophilic polymer technology. Additionally: Diverse applications across multiple industries. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of HYDI?
Yes, most major brokerages offer fractional shares of Hydromer, Inc. (HYDI) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track HYDI's earnings and financial reports?
Hydromer, Inc. (HYDI) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for HYDI earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available company data and may be limited due to the company's OTC listing.
- AI analysis is pending and may provide further insights in the future.